NCT00092287View on ClinicalTrials.gov

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

PHASE3TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 31, 2004

Study Completion Date

October 31, 2004

Conditions
Malignant Carcinoid Syndrome
Interventions
DRUG

lanreotide Autogel (somatostatin analogue)

DRUG

Sandostatin long acting release (LAR) Depot (somatostatin analogue)

Trial Locations (1)

33612

Larry Kvols, MD, Tampa

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00092287 - Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome | Biotech Hunter | Biotech Hunter